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Let’s get specific: the relationship between 
specificity and affinity 
The factors that lead to high-affinity binding are a good fit between the surfaces of the 
two molecules in their ground state and charge complementarity. Exactly the same 
factors give high specificity for a target. We argue that selection for high-affinity 
binding automatically leads to highly specific binding. This principle can be used 
to simplify screening approaches aimed at generating useful drugs. 
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In fields ranging from pharmacology to materials 
science, the affinity and specificity of binding interac- 
tions affect how well molecules serve their function. We 
have been led to consider the rules that govern affinity 
and specificity, and the relationship between them, by 
our work on oligonucleotide ligands discovered via the 
SELEX (systematic evolution of ligands by exponential 
enrichment) combinatorial chemistry protocol [1,2]. In 
its most straightforward application this protocol seeks 
oligonucleotides that bind to a particular target with 
high affinity, and yet high specificity for that target is 
frequently also found. We have come to the conclusion 
that a sufficiently high-affinity ligand can be confi- 
dently expected to be highly specific for its target. 
Here, we describe some observations on surprisingly 
specific target binding by SELEX-derived oligo- 
nucleotides, and the reasons for the correlation between 
affinity and specificity. 
Sources of affinity and specificity 
Electrostatic and hydrophobic effects dominate all attrac- 
tive interactions between two molecules; hydrogen 
bonding is often particularly important, especially in 
nucleic acid recognition. Shape complementarity is also 
crucial.The highest possible affinity toward a target mol- 
ecule would be obtained with a ligand having a perfect 
mirror image of the shape of the target surface, with a 
charge distribution perfectly complementing that of the 
desired target surface. Conformational flexibility can be a 
major factor limiting the affinity and specificity of inter- 
actions. Molecules that can easily undergo induced fit 
will be able to interact with a variety of targets, but will 
pay the price of decreased affinity due to a conforma- 
tional energy penalty. On the other hand, molecules with 
well defined solution ground states that naturally com- 
plement the desired target will bind to fewer targets, but 
will do so with higher afi5nities.A truly ideal ligand will 
exhibit dynamic motions that are in tune with those of 
the target, so that both molecules can flex in concert, 
minimizing the loss of entropy on binding. 
Chemists working on drug development have pursued 
several approaches to producing the ideal ligand, ranging 
from the traditional (and still the most successful) approach 
of natural product screening followed by systematic modi- 
fication, to rational design, to combinatorial chemistry. 
The appeal of combinatorial chemistry is that, depending 
on the library size, a large array of interaction geometries 
can be explored simultaneously. A superior combinatorial 
drug discovery process would select for optimum interac- 
tion, electrostatic and hydrophobic, between the drug 
lead and the target, providing high affinity binding. As 
noted above, the process would ideally select molecules 
with a well defined ground state that do not have readily 
accessible tautomers or conformers; unless this is the case, 
the assay will frequently select ligands that require in- 
duced fit to bind to their targets, reducing their likely 
affinity and specificity. The ideal selection process must 
also allow the identification of very rare components of 
the library as tight-binding ligands, for example by 
allowing reiterative amplification and re-selection of com- 
ponents of the library. Our own focus, SELEX, is a reitera- 
tive combinatorial chemistry technology that meets all of 
these criteria. 
Nucleic acids as drugs 
The structural diversity of drugs is enormous. Approved 
drugs range from small, orally active, organic molecules 
to large proteins with molecular weights of up to 
200 kD. The diversity of investigational drugs is even 
larger. What, then, defines a drug? One definition would 
be that a drug is any molecule that causes a desired alter- 
ation in metabolism or physiology by binding to a spe- 
cific target molecule (or to a small number of targets). 
Any combinatorial system that routinely produces high- 
affinity ligands for target molecules therefore has a good 
chance of producing potential drug candidates. 
Nucleic acids have turned out to be surprisingly good at 
generating high-affinity ligands for a variety of protein 
and small molecule targets. Ligands for over 100 protein 
targets have been developed using SELEX, generally 
with affinities in the nM range or better. One major 
reason for this success appears to be the relative rigidity 
of nucleic acids compared to peptides or other poly- 
meric structures. Most of the functional groups that are 
involved in binding to target molecules are only one 
atom removed from the ring of a base or a sugar, with 
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Fig. 1. Structural motifs for SELEX ligands. The four distinct 
motifs, (a) hairpin stem, (b) symmetric and asymmetric bulges 
flanked by helical regions, (c) pseudoknot, and (d) G quartet, are 
shown as three-dimensional models. The ‘single-stranded’ 
regions are colored light blue and the structural regions (helices 
and quadruplexes) are colored magenta. 
the exception of the phosphodiester bond. The confor- 
mational flexibility of these groups is therefore very 
limited. Only the ribose ring, phosphodiester, and glyco- 
sidic bonds have torsional conformations, in contrast to 
proteins (or most polymeric materials) where, in addition 
to the backbone, the sides chains have significant tor- 
sional freedom and numerous conformational states. Base 
pairing further restricts the conformations of the 
monomers within oligonucleotides.These qualities make 
nucleic acids relatively rigid. For a nucleic acid ligand, a 
good fit is really good; a bad fit cannot be accommo- 
dated by ‘induced fit’ because of restricted conforma- 
tional freedom, and therefore is selected against very 
early in the screening process.The ideas we describe here 
were developed from observations on nucleic acids, but 
we believe that they have broader relevance. 
The ligand families found through SELEX to date pri- 
marily fall into four structural motifs (Fig. 1): hairpin 
stems and loops, symmetric and asymmetric bulges 
flanked by helical regions, pseudoknots, and G quartets 
[3] .The binding surfaces in these oligonucleotides 
always include some ‘single-stranded’ domains, probably 
because those domains provide the greatest variation in 
shapes and therefore have the best chance of generating 
a surface complementary to any target. Similarly, the 
binding sites of proteins are often formed from loop 
regions that do not have or-helix or B-sheet secondary 
structure. Only one detailed structure of a SELEX- 
derived oligonucleotide is available [4,5], although 
many such molecules are under study. We believe that 
the ‘single-stranded’ domains of these oligonucleotides 
will be found to be severely constrained through their 
fixed ends, standard and non-standard base pairing 
interactions, and tertiary interactions similar to those 
seen in the handful of oligonucleotide structures that 
have been determined [6-81. Thus, the structured 
regions of these oligonucleotides are unlikely to reside 
solely in their helical regions. 
The importance of being specific 
Specificity is important both for drug discovery and for 
toxicity profiles. As more and more drugs are developed 
to inhibit particular molecular targets, it seems reasonable 
that extreme specificity of a potential drug for the 
intended target will be important. Many ideas about 
which target is the right one to use to treat a particular 
disease will be wrong, since our understanding of 
biology is far from perfect; to go forward from a right 
idea or to discard a wrong idea requires data that defini- 
tively show that a given compound, which inhibits the 
activity of its target completely and specifically, does or 
does not affect the course of a disease in an appropriate 
animal model (or in a human clinical trial).The overall 
process of drug discovery is thus facilitated by experi- 
ments with highly specific compounds. And, of course, a 
highly specific drug would be expected to have fewer 
side effects, simplifying the process of evaluating the 
results of a clinical trial. 
How to achieve high specificity? 
What are the strategies available for identifying mole- 
cules that bind to a target of interest with high speci- 
ficity? Since we know relatively little about the 
environment in which the ligand will have to show 
highly specific binding, and what the molecules compet- 
ing with the target for ligand binding may be, the best 
approach we can take is to select for optimum interac- 
tion, electrostatic and hydrophobic, between the drug 
candidate and the target,with good shape complemen- 
tarity - in other words, to select for high affinity. We 
have used the SELEX protocol to screen for high-affinity 
ligands for a number of proteins and small molecules. 
The procedure is diagrammed in Figure 2; a pool of 
random oligonucleotide sequences are allowed to bind to 
a target, poor binders are discarded, and good binders are 
amplified for re-selection. Note that there is no element 
of selection for lack of binding to undesired targets in 
this strategy (although such counter-selection steps have 
been added in variations on this theme). Because it is 
possible to amplify selected pools directly in a nucleic 
acid library, the protocol allows one to search for com- 
pounds that are present at a very low level (perhaps at 
levels of 10-9-10-13 [l]), which would be impossible to 
detect in a small-molecule or conventional peptide com- 
binatorial library (amplifiable peptide libraries also exist, 
however; see [9]). 
As noted above, it is possible to identify nucleic acid 
ligands for diverse protein targets using SELEX. We have 
also studied -20 small molecule targets. The highest 
affinity small-molecule ligand reported thus far has a K, 
of -100 nM [l]. There are probably two reasons why 
ligands to small molecules typically have lower affinities 
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than to protein targets. First, many of the small molecule 
targets have been less rigid than the protein targets, and 
thus must themselves become conformationally fixed 
upon binding to the oligonucleotide ligand; thus, an 
entr0pi.c cost is paid as the target becomes more struc- 
tured than it was before binding [lo]. Second, the area 
over which interaction with a small molecule must take 
place is inevitably smaller than the area of interaction 
with a protein, reducing the number of functional 
groups available for binding interactions. High affinity 
can therefore be achieved only with exquisite shape and 
interaction complementarity over the few interaction 
sites available. 
The SELEX-derived ligands do have remarkable speci- 
ficity, however. Oligonucleotide ligands have been identi- 
fied that can discriminate D versus L amino acids 
[ll-131, reduced versus oxidized cofactors [14], theo- 
phylline versus caffeine [15], and ATP versus other 
purine nucleotides [16]. How does this high specificity 
arise from a selection process that is designed to identify 
high-affinity b’ d m ers? How can relatively low-affinity 
binding lead to exquisitely specific binding? 
Binding events and specificity 
Specificity is a term used to describe a wide variety of 
processes in molecular biology, including enzyme kinet- 
ics, gene regulation, and drug molecule interactions. In 
this discussion, we will take specificity to refer to a func- 
tional discrimination between molecules competing for a 
common ligand. Such discrimination is usually the result 
of differences in the free energy of interaction for the 
Fig. 2. Diagram of the SELEX procedure. A library composed of 
1014 to 1015 sequences of single-stranded oligonucleotides is 
assembled. Each sequence contains a random region flanked by 
fixed sequences, denoted A and B here, that permit amplification 
and transcription. A round of SELEX begins by allowing the library 
to interact with the target, followed by a selection procedure, and 
finally pool amplification of the selected population. After sever- 
al rounds the resulting population is cloned and sequenced. See 
[I ,9] for details. 
Box 1. The binding events that govern specificity. 
Consider a protein target P that binds to its natural substrate 
S with an equilibrium binding constant Ks that relates the 
concentrations of the complexed and uncomplexed species, 
thus: 
P + S m P:S ; Ks = [P:S] / [PI[S] (1) 
where P:S is a non-covalent complex. Similarly, a second 
ligand, L, binds to P with a constant K, and competes with S. 
P + L --L P:L ; K, = [P:L] / [P][L] (2) 
L may be an inhibitor of P when P is an enzyme, or an antag- 
onist or agonist of P when P is a signaling protein, for 
example. The relative affinities and concentrations of S and L 
for P will largely determine the biological response on P due 
to L; these considerations are most important when consider- 
ing efficacy. But molecule L may interact with a variety of 
other proteins, Bis, in the system: 
Bi + L @ Bi:L; Ksi = [Bi:L]/[Bi][L] (3) 
lowering its effective concentration and altering its efficacy. 
We can define a measure (01~) for the discrimination of L for 
its specific site P relative to the nonspecific sites (Bis) as 
(YS = lP:Ll / Bi [Bi:Ll, or, or, = Kt [PI [L] /‘pi K,iIBil IL] (4) 
where s, varies from 0 for poor specificity to infinity for high 
specificity. It is apparent by inspection that the specificity of 
binding does not depend on the concentration of L, thus 
01~ = I<, [PI /xi KaJBJ. 
Thus, the specificity of binding is determined by the ratio of 
the product of the K, and concentration for the desired 
binding event to the sum of the product of Kd and concentra- 
tion for all other interfering binding events. 
molecules of interest, although kinetic discrimination can 
presumably exist for some systems. From a thermo- 
dynamic viewpoint, specificity can be defined by consi- 
dering the coupled equilibria between species in solution. 
This analysis (after von Hippel and Berg, [17]) is shown in 
Box 1, from which it is easy to see that the specificity 
term, (Ye, is the ratio of the product of K, and concentra- 
tion for the target protein P to the sum of the product of 
K, and concentration for all other competing species. 
Thus, there is no relationship between specificity and the 
absolute affinity of L for target P It is therefore possible to 
have high specificity with relatively low affinity provided 
that KL >> KBi for all Bi, when P and Bi are similar in 
concentration. The larger the aggregate concentration of 
Bi, the greater the difference between K, and KBi 
required to give a desired level of specificity. 
What is the effect on specificity of systematically increas- 
ing the affinity of a ligand for a particular target? 
Typically, this will result in higher specificity; the interac- 
tions that lead to high affinity of L for P will usually not 
lead to similar increase in binding affinity for all B,. 
Increased affinity is achieved through increasingly exact- 
ing geometric dispositions of functional groups in the 
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ligand/target complex and these detailed geometries of aimed at identifying high-aftinity ligands for basic fibrob- 
functional groups are not shared by the background last growth factor (bFGF) [21]. This ligand binds in the 
binders. Even if one background binder does show 
increased affinity, it is highly unlikely that all of them will; 
heparin-binding site, a basic domain of the protein. The 
other members of the FGF protein family [22] also have a 
indeed, there must be at least an equal likelihood that basic domain, and yet the selected ligand is not bound 
changes that increase binding to P will decrease binding tightly by those proteins. Similarly, the ligand fails to bind 
to one or more Bi (although decreases in the affinity with tightly to other heparin-binding proteins. Comparable 
which the low-affinity competitors bind to the ligand data have been obtained for the ligand that binds to vascu- 
will not be as important as changes in the affinity of the lar endothelial growth factor [23], for which even more 
high-affinity competitors). On average, therefore, the highly specific ligands are reported in a paper in this issue 
term zi Kni[Bi] would be expected to increase less than [24], and also for the ligand that binds to keratinocyte 
the term KJP]. growth factor (N. Pagratis et ul., personal communication). 
For nucleic acid drugs, the class of molecules that can act 
as non-specific binders (Bi) may be particularly diverse. 
Many proteins bind all nucleic acids non-specifically, with 
affinities in the p,M range. This suggests that diagnostic 
and therapeutic oligonucleotides should have nM affinities 
or better if they are to be useful; although this goal has 
been successfully achieved for protein targets, it appears to 
be harder to reach for small molecule targets. 
HIV-1 reverse transcriptase 
One example of surprisingly specific binding resulting 
from selection for high-affinity binding is the SELEX- 
derived RNA ligand for human immunodeficiency virus-l 
reverse transcriptase (HIV-l RT) [18]. The winning family 
(see Fig. 3) of RNAs that bound to HIV-1 RT formed an 
obvious pseudoknot structure, based on the covariation of 
nucleotides that form base pairs. The winning RNA 
ligands bound to HIV-l RT with K,s in the nM range, as 
did ligands isolated from single-stranded DNA libraries 
[19]. Most importantly, and surprisingly, the HIV-l RT 
ligands bound poorly to avian myeloblastosis virus (AMV), 
murine moloney leukemia virus (MMLV), and feline 
immunodeficiency virus (FIV) RTs [l&20] .This is particu- 
larly surprising since these ligands bind to the active site of 
HIV-l RT, and the active sites of all of the viral RTs tested 
are expected to be very similar, since they all have the task 
of binding to similar primer-template complexes to initiate 
DNA synthesis. Indeed, ligands that were identified for 
AMV MMLV or FIV RTs are also each exquisitely specific 
for their own target [20]. 
The binding affinity of one of the bFGF ligands has been 
determined for five related proteins from the FGF family 
and for four heparin binding proteins and is presented in 
Table 1. The table also shows the specificity measure et, 
defined in Box 1 for competition between the desired 
target and nonspecific targets (in this case, a single alterna- 
tive binder) and the related measure f, (the fraction of 
ligand bound to the desired target, calculated as 
[p:L]/(L,,,,&]), or f,= (l+a,l)-l.The ligand binds to the 
native bFGF protein with a K, of 3.5 x lo-lo M, whereas 
the next best affinity, for FGF-5, is two orders of magni- 
tude lower. The specificity descriptors were computed 
using a total protein concentration of 1.0 x 10e9 M for 
each species and a total ligand concentration of 1.0 x lOpa 
M to ensure saturation of the specific site in the absence of 
Table 1. Specificity of ligand for native bFGF. Relative binding 
affinity (KdbFCF/KdProtein) of ligand for proteins from the FGF 
family of proteins and for several heparin-binding proteins. 
Proteina &bFCF/$protein b % 5 
Selectivity for one member of a family 
Finding a ligand that binds selectively to an enzyme from 
one virus and not to similar enzymes from related viruses 
may be surprising, but is not especially physiologically 
important. A more relevant story comes from experiments 
aFGF (FCF-1) 3.6 + 0.4 x 1 O-4 103.1 0.99 
K-FCF (FGF-4) 6.2 k 2.2 x lOA 60.3 0.98 
FGF-5 4.1 * 1.4 x 1 o-2 1.9 0.65 
FGF-6 5.7 + 0.8 x 104 65.5 0.98 
KGF (FGF-7) 7.8 f 0.9 x lOA 48.2 0.98 
VEGF 8.2 f 0.9 x lOA 45.9 0.98 
PDGF AB 2.5 + 0.3 x 1O-3 15.8 0.94 
Antithrombin III 8.2 + 1.2 x 1 O-6 4483.5 1 .oo 
Thrombin 3.1 I!Y 0.5 x IO-5 1186.7 1.00 
aAbbreviations: aFGF: acidic FGF; KGF: keratinocyte growth 
factor; VEGF: vascular endothelial growth factor; PDGF A&: 
I? 
latelet-derived growth factor, AB isoform. 
The KdbFCF value of 3.5 + 0.3 x IO-lo M for ligand min24Nt 
(5’-GGUGUGUCGAAGACAGCGGGUGGUUC-3’) is used 
for computing the relative affinities. 
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nonspecific binding.The individual values of (Y, range from 
1.9 to over 4500, while the fraction of specific sites occu- 
pied, f, varies from a low of 0.65 to a high of 1 .O. 
If all of the proteins listed in Table 1 were present 
together at the same concentration in vim, (Y, would be 
1.5 and f, 0.60. Only FGF-5 binds a significant amount of 
the ligand that was selected to have high affinity for 
bFGF; when 60% of the bFGF molecules in the mixture 
are bound to ligand, 35% of FGF-5 molecules will be 
bound as well. 
The problem of closely-related targets 
Our premise, as discussed above, is that selection for very 
high affinity b’ d’ m mg will inevitably produce ligands with 
a high ou,.The example of the FGF growth factor family 
shows this, but also illustrates the main problem with an 
approach that selects only for high-affinity binding; an 
alternative target that is sufficiently closely related to the 
desired target will continue to be an effective competitor 
even at very high levels of affinity (in this case a K, of 
0.35 nM). Selecting for even tighter binding would, we 
believe, eventually give selective binding even when the 
competitor is closely related. If the competing target is 
known, however, it is usually more expedient to select 
against unwanted binding. A protocol called counter- 
SELEX has been developed for this purpose, and has 
been used to identify oligonucleotide ligands that selec- 
tively bind to theophylline, but not to caffeine.The two 
structures differ only at N7 where a hydrogen in theo- 
phylline is replaced by a methyl group in caffeine (Fig. 
4); the ligand discriminates against caffeine by greater 
than 10 OOO-fold [15]. 
The effect of non-specific binding on specific binding 
To consider the kind of competition that may occur in 
viva in a more quantitative way, we have calculated the 
binding parameters for a ligand aimed at a target mole- 
cule present at 25 nM concentration, which is the average 
protein concentration for an organism with 100 000 
different proteins of average mass 40 kD at a total con- 
centration of 100 mg ml-l.The ligand is assumed to have 
a K, for the target protein of lo-lo. The fraction of the 
target protein bound - [P:L]/P,,,d - is calculated as a 
function of ligand concentration (Fig. 5).The figure also 
shows the fraction of protein-bound ligand that is bound 
to the intended target, f,. For the simplest case, with no 
C!H, 
I 
CH3 
Theophylline Caffeine 
Fig. 4. The structures of theophylline and caffeine. 
Fig. 5. The effects of nonspecific sites on specific binding. The 
yellow curves are the fraction of specific target bound by ligand, 
P:L, with 0.1 nM affinity, relative to Protat as a function of ligand 
concentration [L] for (squares) no nonspecific sites, (circles) 
100 000 sites with 0.1 mM affinity and (crosses) 100 sites of 1 nM 
affinity plus 100 000 sites at 0.1 mM affinity. The green lines are 
the specific fraction of L bound, f,, as a function of [L] using the 
same marker coding as above. 
other protein in the system, f, = 1; all binding occurs to 
the specific target. 
Let us now imagine that all 100 000 proteins, each 
present at 25 nM, have nonspecific binding at the same 
low affinity, having a K, of 10p4. (This is in the same 
range as the level of nonspecific binding shown for com- 
petitors such as thrombin, which are not FGF family 
members, in the bFGF example, above). In this case the 
binding of the ligand to the intended target occurs to 
nearly the same extent as when only the intended 
protein is in the system. Even when the target protein is 
90 % saturated with ligand, roughly half of the ligand 
bound to protein is bound to the intended target. More 
importantly, the 100 000 proteins, each present at 25 r&I, 
will themselves be bound with ligand to a negligible 
extent, since the ligand not bound to the intended target 
will distribute uniformly on all 100 000 proteins. In this 
situation there will be no effect on the activity of any of 
these 100 000 proteins. 
In the final case, we have added 100 proteins with a K, of 
lop9 to the system, in addition to the 100 000 proteins 
with low affinity. This has two major effects.First, the 
amount of ligand needed to saturate the intended target is 
nearly lOO-fold higher than in the other two cases. 
Second, and more importantly, the fraction of ligand that 
is bound to unintended proteins when the intended 
target is near saturation is very high. The ligand could 
therefore affect the activities of any of these proteins, 
assuming that it binds to a site that is important for the 
function of the protein. At 90 % saturation, 1.86 % of the 
bound ligand occupies the intended target and 47 % of 
each protein with nM affinity will be occupied. This 
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graphically illustrates the problem with unintended vari- 
ables in an animal experiment or a human clinical trial. In 
the real situation, these 100 proteins will almost all be 
unidentified, and it is thus hard to imagine a strategy that 
could directly increase the specificity of a ligand by 
selecting against binding to the unintended targets. 
Fortunately, this model is probably not realistic; when a 
ligand reaches a K, of 10-l’, it is likely to be highly spe- 
cific for its intended target, and to cross-react significantly 
with only a few closely-related proteins (as is the case for 
the bFGF ligand described above). Thus, in most drug 
discovery efforts, aiming for very high affinity of binding 
may be sufficient to give a high enough selectivity for a 
compound to be clinically useful. 
Although in this article we have focused on the potential 
of selection based on equilibrium thermodynamics, it 
should be noted that this is not the only strategy available. 
For example, it is possible to evolve ligands that irre- 
versibly crosslink their targets with high specificity and 
affinity [25]. It is also possible to direct binding and 
crosslinking specifically to the active site of an enzyme 
[26]. For the p ur p oses of SELEX-based drug develop- 
ment, it is encouraging that, so far, it has been possible to 
use SELEX to identify high-affinity ligands no matter 
what the target. That these high-affinity ligands are truly 
specific for their intended target can be shown by assaying 
them in the presence of whole blood or serum; the pres- 
ence of multiple alternative protein targets does not inter- 
fere with the binding of these ligands to their intended 
target. It seems certain that nucleic acid based drugs will 
soon become a standard feature of the pharmacological 
landscape, both as diagnostics and as therapeutics. 
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